CC
Publicaties op Oncologisch.com
Cemiplimab in recurrent cervical cancer: Final analysis of totale overleving in the phase III EMPOWER-Cervical 1/GOG-...
Pembrolizumab plus CRT bij cervixcarcinoom: ENGOT-cx11/KEYNOTE-A18 OS update
Pembrolizumab plus chemoradiatie bij cervixcarcinoom: ENGOT-cx11/GOG-3047/KEYNOTE-A18 fase III
Cemiplimab bij recidief cervixcarcinoom: PROs EMPOWER-Cervical 1
Cemiplimab en overleving bij recidief cervixcarcinoom: EMPOWER-Cervical 1 fase III